Kunena :: Тема: Posted by Norma on 29.11.2016 15:45:35: erlotinib dialysis (1/2)

Навигация: Главная Форум Главный раздел Сообщество базовых площадокPosted by Norma on 29.11.2016 15:45:35: erlotinib dialysis

Добро пожаловать, Гость

Форум

Главный раздел

Сообщество базовых площадок

Posted by Norma on 29.11.2016 15:45:35: erlotinib dialysis

Страница:
1
2

ТЕМА: Posted by Norma on 29.11.2016 15:45:35: erlotinib dialysis

Posted by Norma on 29.11.2016 15:45:35: erlotinib dialysis 7 года 5 мес. назад #918

akipk

High Quality - Low Cost Anti-Cancer Drugs

*
Dr. West, My husband (41 year old non-smoker with stage IIIB, with pleural effusion) had 6 full cycles of taxol/carboplatin with Avastin every 3rd week, (actually an additional 2 weekly infusions of the taxol/carbo combo too) and then went straight to taking both Avastin and Tarceva. It’s only been 4 months, but there’s been no progression so far. The insurance company is now saying it will not cover Tarceva and it seems that our doctor is unwilling to push for this. It seems to me that the BeTa study used a group that is different from my husband- he has not progressed as I understand the study group had before entering the study. Plus, the secondary endpoint of progression-free survival showed promise, so it doesn’t seems like the insurance company should do this. It’s true we don’t really know what is preventing progression, for all we know it’s the mushroom extract or the Essiac tea he drinks, but I am unwilling to do what the doctor now proposes (with no pushback against the insurance company), which is to put him on just Avastin and wait until he progresses and then put him back on Tarceva. We’d like to prevent progression as long as possible, and that seems an appropriate treatment goal, and one that the insurance company should not have the right to alter. Moreover, they have informed the doctor that if we get the Tarceva some other way (like through the pharmaceutical’s assistance program) they would no longer pay for Avastin. So, I guess my question is, since this announcement re: the BeTa study, is there truly no support for taking the two together- seems to me the secondary endpoint of PFS does support use of the combination? I am hopeful that if there is support for the combination, we can get our doctor to push back a little and keep my husband on both. Thanks for your assistance, Sarah
Thank you, for those grading charts Certain Spring. I think the oncologist believes that if the rash becomes really severe nothing much helps except stopping the the Tarceva.
I don't think Tarceva is that kind of a pill and splitting it may make its absorption dangerously different. Also, from my experience skipping one dose every now and then, if the side effects become unbearable, will not work for Tarceva. It took my dad more than one month after discontinuing to get rid of the spots and the rash, so it simply does not work this way.
surovikino-crb.ru/index.php/forum/dobro-...st-without-insurance
Erlotinib monotherapy is approved for treatment of patients with advanced or metastatic NSCLC, while bevacizumab monotherapy is not standard for NSCLC treatment [ 5. 7 ]. The objective of our study was to determine whether there were conditions under which the addition of bevacizumab would enhance antitumor activity of erlotinib against NSCLC tumors in vitro and in vivo. First, we found that erlotinib plus bevacizumab were no extra inhibitory than erlotinib alone in vitro. This result is consistent with those of a previous study [ 21 ] and may be explained by the fact that VEGFR is expressed on vascular endothelium but not on malignant cells in human solid tumor types (including lung cancer) [ 28 ]. Because the change of erlotinib concentration is undetectable in erlotinib-sensitive tumor due to effective apoptosis induction to the cancer cells with low level of erlotinib, we then produced xenograft models bearing primarily erlotinib-resistant NSCLC cells to investigate the erlotinib accumulation in the tumor with bevacizumab combination. We found that the tumors expressing higher levels of VEGF protein were more responsive to inhibition by bevacizumab and combination treatment. These results suggest that the effect of dual inhibition of EGFR and VEGF is dependent on VEGF expression in EGFR TKI-resistant xenografts. Finally, we demonstrated a trend toward increasing concentrations of erlotinib in the tumor tissues during treatment with erlotinib and bevacizumab compared with erlotinib alone. This effect also appeared to be influenced by the levels of VEGF protein.
Seventy-six patients were evaluated at time of data presentation and treated with Tarceva at 150mg / day. Partial response was noted in 8 patients (12 percent) and 32 patients (48 percent) had stable disease of the 66 patients evaluable for response. Median survival was 11 months and median duration of partial response has not been reached. Median survival for patients with stable disease was 12 months. Tarceva demonstrates encouraging activity as a front-line treatment in patients 70 years of age and older with previously untreated advanced NSCLC.
alliance.pp.ua/index.php?option=com_kune...1&id=1075&Itemid=145
TG101348 enhance erlotinib-induced apoptosis and inhibit expression of STAT3 expression in vivo
Digitoxin may decrease the cardiotoxic activities of Erlotinib.
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Important: The information below refers to medicines available in the United States that contain erlotinib.
Background: EGFR inhibitor ; Erlotinib inhibits EGFR tyrosine kinase autophosphorylation by inhibition of the intracellular domain. Studies in cell lines and enzyme assays have both shown that erlotinib inhibits EGFR at concentrations significantly lower than those needed to inhibit c-src and v-abl .
J. Porter et al. A dose escalation and pharmacokinetic (PK) trial of weekly docetaxel combined with daily erlotinib in adult cancer patients. J. Clin. Oncol.2004, 22, 14S, 2119.
muzo.ru/blogs/post/58036
. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007 ; 25. 4743 - 4750.
45. The process as claimed in claim 44, wherein the erlotinib hydrochloride crystalline particles having mean particle size (D 50 ) ranging from about 4.6 μm to 9.5 μm and 90 volume-% of the particles (D 90 ) ranging from about 14.6 μm to 24.5 μm.
Development and validation of high performance liquid chromatographic method for the determination of Erlotinib
The process of the invention may be carried out by a) reacting 4-chloro-6,7-bis-(2-methoxyethoxy)-quinazoline with 3-ethynylaniline or its hydrochloride salt in a solvent medium comprising dimethylsulfoxide and an alcoholic solvent in the presence or absence of a base; and b) isolating erlotinib as free base or a pharmaceutical acceptable acid addition salt substantially free of N-methoxyethyl impurity.
shashki.zp.ua/index.php?option=com_kunen...tmenu=148&Itemid=146
As the primary type of lung cancer, non-small-cell lung cancer (NSCLC) has received growing attention from the researchers [ 1 - 3 ]. It is reported that about 85% of all the lung cancer patients are diagnosed as NSCLC [ 4 ]. One strategy commonly used in the treatment is to target the tyrosine kinase (TK) domain of epidermal growth factor receptor (EGFR) to interrupt the downstream signaling [ 5. 6 ]. Reversible tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, are generally applied in this procedure. They are proven to be efficient for patients over a period of time, but a limited treatment outcome usually occurs because of mutation at EGFR TK domain [ 7. 8 ]. According to statistics, about 10% to 15% of white patients and 30% East Asian patients experience a mutation of EGFR TK domain [ 4 ], and over one hundred mutation types have been found so far [ 9. 10 ].
Afatinib vs Erlotinib head-to-head trial results
Erlotinib is not recommended for treating locally advanced or metastatic NSCLC that has progressed after non-targeted chemotherapy in people with tumours that are EGFR-TK mutation-negative.
Subjects with a known immediate or delayed hypersensitivity or untoward reaction to paclitaxel, trastuzumab, carboplatin, or other related compounds, or to drugs chemically related to lapatinib. These include other aminoquinazolines. such as gefitinib (Iressa), erlotinib (Tarceva), or other chemically-related compounds.
In the table 2. the binding constants, K 0 . and binding sites, n, for erlotinib hydrochloride associated with BSA are listed. The correlation coefficients are larger than 0.98 indicating that the interaction between erlotinib hydrochloride and BSA is well in agreement with the site-binding model underlined in Eq. [2]. The K values for association of erlotinib hydrochloride with BSA increased by the rise in temperature which may indicate the formation of a stable complex at higher temperatures (10 ) and it is consistent with the dynamic quenching mechanism obtained for the interaction of erlotinib with BSA. Dynamic quenching which depends on collisions between the excited state and the quencher is a diffusion-controlled process, and increases with temperatures. The obtained values for n were found to be 1 indicating that only a single binding site exists in BSA for erlotinib hydrochloride molecules. This number is in agreement with the reported numbers (5 ) Figure 3
To determine whether the inhibition of these signaling pathways translates in reduced MRP-mediated or P-gp-mediated efflux in our model, we evaluated the activity of PP2, LY294002 and rapamycin on the intracellular accumulation of calcein and DiOC 2 (3), respectively. None of these pathway-specific inhibitors could increase the retention of calcein and DiOC 2 (3) ( Fig. S2A–D ), even though all diminished (to a variable extent) the exposure of P-gp on the cell surface ( Fig. S2E and F ). These data indicate that the pathway-specific inhibition of SRC- and mTOR-conveyed signals fails to recapitulate the effects of erlotinib on the cell surface exposure and functionality of P-gp.
For further information please call 1-877-Tarceva (1-877-827-2382).
domkolbaski.ru/forum/3--/80916-posted-by...-erlotinib-2014.html
PURPOSE: This randomized phase II trial is studying how well giving erlotinib hydrochloride together with celecoxib works compared with erlotinib hydrochloride alone in treating patients with stage IIIB-IV non-small cell lung cancer.
I've had two CT scans since starting the Tarceva and my tumors continue to skrink which has been really good news. It is also good news about your brain tumors shrinking. I'll pray that they all continue to shrink. It's scary to go through the tests and have to make decisions on what to do and how to proceed. I hope you are feeling well and have a good support system. Right now I feel great and the only side effects encountered so far is the diarrhea which is controlled with Immodium. My children and grandchildren have been a great source of support in teaching me what is truely important in life. My sister and have I been traveling while I'm still well enough to enjoy it. Tomorrow we leave for Williams Az to take the train to the southern rim of the Grand Canyon then 3 days in Las Vegas.
cosmo-parts.ru/index.php/kunena/dobro-po...ib-contraindications
Erlotinib (Tarceva ® ) in Second/Third Line Treatment for Non-Small Cell Lung Cancer (NSCLC) – Case Description
Please cite this article as: Márquez-Medina D, et al. Virus del papiloma humano en cáncer de pulmón no microcítico. Impacto de mutaciones del EGFR o respuesta a erlotinib. Arch Bronconeumol. 2013;49:79–81.
The combination of erlotinib plus bevacizumab as first-line treatment results in significantly longer progression-free survival than erlotinib alone in patients with EGFR mutation–positive advanced NSCLC.
shashki.zp.ua/index.php?option=com_kunen...=3&id=658&Itemid=146
Tarceva (cloridrato de erlotinibe) está indicado para o tratamento de pacientes com câncer de pulmão de não-pequenas células (CPNPC), localmente avançado ou metastático (estadios IIIb e IV), após a falha de pelo menos um esquema quimioterápico prévio.
Global Research On Tarceva Market Analysis and Forecasts to 2015 - By Acute Market Reports
If it’s felt that a dose reduction is appropriate, we’d usually drop the dose to 100 mg daily. Tarceva is available in tablets at the starting dose of 150 mg daily, as well as 100 and 25 mg tablets.
Näheres zu Tarceva